These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7691462)

  • 41. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
    Foa R; Norton L; Seidman AD
    Int J Clin Lab Res; 1994; 24(1):6-14. PubMed ID: 7910054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.
    Spencer CM; Faulds D
    Drugs; 1994 Nov; 48(5):794-847. PubMed ID: 7530632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review.
    Guchelaar HJ; ten Napel CH; de Vries EG; Mulder NH
    Clin Oncol (R Coll Radiol); 1994; 6(1):40-8. PubMed ID: 7909688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Taxol: a new and effective anti-cancer drug.
    Slichenmyer WJ; Von Hoff DD
    Anticancer Drugs; 1991 Dec; 2(6):519-30. PubMed ID: 1687206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Taxol in ovarian cancer.
    Runowicz CD; Wiernik PH; Einzig AI; Goldberg GL; Horwitz SB
    Cancer; 1993 Feb; 71(4 Suppl):1591-6. PubMed ID: 8094322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paclitaxel in cancer therapy.
    Mekhail TM; Markman M
    Expert Opin Pharmacother; 2002 Jun; 3(6):755-66. PubMed ID: 12036415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer.
    Jamis-Dow CA; Klecker RW; Sarosy G; Reed E; Collins JM
    Cancer Chemother Pharmacol; 1993; 33(1):48-52. PubMed ID: 7505722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overview of paclitaxel (TAXOL).
    Martin V
    Semin Oncol Nurs; 1993 Nov; 9(4 Suppl 2):2-5. PubMed ID: 7904376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical toxicities encountered with paclitaxel (Taxol).
    Rowinsky EK; Eisenhauer EA; Chaudhry V; Arbuck SG; Donehower RC
    Semin Oncol; 1993 Aug; 20(4 Suppl 3):1-15. PubMed ID: 8102012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Paclitaxel (taxol).
    Kohler DR; Goldspiel BR
    Pharmacotherapy; 1994; 14(1):3-34. PubMed ID: 7909150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Paclitaxel (taxol).
    Rowinsky EK; Donehower RC
    N Engl J Med; 1995 Apr; 332(15):1004-14. PubMed ID: 7885406
    [No Abstract]   [Full Text] [Related]  

  • 52. Patient care issues: the management of paclitaxel-related toxicities.
    Finley RS; Rowinsky EK
    Ann Pharmacother; 1994 May; 28(5 Suppl):S27-30. PubMed ID: 7915156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paclitaxel-induced neuropathy.
    Postma TJ; Vermorken JB; Liefting AJ; Pinedo HM; Heimans JJ
    Ann Oncol; 1995 May; 6(5):489-94. PubMed ID: 7669713
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trials.
    Burris HA
    Ann Pharmacother; 1994 May; 28(5 Suppl):S7-10. PubMed ID: 7915158
    [No Abstract]   [Full Text] [Related]  

  • 55. A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs.
    Khanna C; Rosenberg M; Vail DM
    J Vet Intern Med; 2015; 29(4):1006-12. PubMed ID: 26179168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paclitaxel (Taxol)--a guide to administration.
    Preston NJ
    Eur J Cancer Care (Engl); 1996 Sep; 5(3):147-52. PubMed ID: 9117048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Taxol dose intensification and its clinical implications.
    Sarosy G; Reed E
    J Natl Med Assoc; 1993 Jun; 85(6):427-31. PubMed ID: 8103561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A preliminary risk-benefit assessment of paclitaxel.
    Bitton RJ; Figg WD; Reed E
    Drug Saf; 1995 Mar; 12(3):196-208. PubMed ID: 7619331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Taxol effect: bizarre mitotic figures (abnormal spindle asters) in a malignant peritoneal effusion: report of a case.
    Jordan CD; Wells WA
    Diagn Cytopathol; 1997 Sep; 17(3):209-12. PubMed ID: 9285194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel.
    Treat J; Damjanov N; Huang C; Zrada S; Rahman A
    Oncology (Williston Park); 2001 May; 15(5 Suppl 7):44-8. PubMed ID: 11396365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.